Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDNF Levels and Treatment of Major Depressive Disorder
2008-008918-39Phase 4Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paroxetine and bupropion in major depressive disorder (MDD) and Bipolar II disorder (BP-II) (3 arms), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Baseline comparison of BDNF levels between patients and controls. Started Mar 2009; status: active.
02
Drugs
paroxetinebupropion
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2008-008918-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008918-39.